Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438512 | 0.89 | GPR35 (0.61) | MEN1KMT2AHTTLMNACA1 | |
| SCHEMBL5082940 | 0.89 | GPR35 (0.61) | MEN1KMT2AHTTLMNACA1 | |
| SCHEMBL19130504 | 0.84 | MEN1 (0.72) | MEN1KMT2AHTTLMNACA1 | |
| SCHEMBL11776456 | 0.81 | TDP1 (0.57) | MEN1KMT2AHTTLMNAGALR3 | |
| SCHEMBL14369940 | 0.81 | TSHR (0.52) | MEN1KMT2AHTTLMNAGALR3 | |
| SCHEMBL28383105 | 0.79 | FFAR1 (0.41) | MEN1KMT2AHTTLMNAGALR3 | |
| SCHEMBL7928377 | 0.79 | TSHR (0.45) | MEN1KMT2AHTTLMNAGALR3 | |
| SCHEMBL3607570 | 0.79 | HTT (0.52) | MEN1KMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL1647499 | 0.79 | ALDH1A1 (0.56) | HTTLMNASMN1; SMN2L3MBTL1GPR35 | |
| SCHEMBL9807406 | 0.78 | CA1 (0.52) | LMNACA1CA2ALDH1A1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110862349-B | Edaravone analogue, and preparation method and application thereof | 南京医科大学 | 2023-05-05 | — | — | CN | disclosed |
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| CN-112119077-A | Kinase inhibitors | 曼彻斯特大学 | 2020-12-22 | — | — | CN | disclosed |
| CN-110862349-A | Edaravone analogue and preparation method and application thereof | 南京医科大学 | 2020-03-06 | — | — | CN | disclosed |
| EP-2373605-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | UNIV DUNDEE (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8507724-B2 | Compounds for use in the treatment of pain | THE UNIVERSITY OF DUNDEE (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507724-B2 | Compounds for use in the treatment of pain | THE UNIVERSITY OF DUNDEE (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20120029235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | THE UNIVERSITY OF DUNDEE (GB) | 2012-02-02 | — | — | US | disclosed |
| US-20120029235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | THE UNIVERSITY OF DUNDEE (GB) | 2012-02-02 | — | — | US | disclosed |
| WO-2010067069-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | THE UNIVERSITY OF LIVERPOOL (GB) | 2010-06-17 | — | — | WO | disclosed |
| EP-0995743-B1 | Derivatives of dihydro- and tetrahydrochinoline as a medicinal antioxydans | SERVIER LAB (FR) | 2003-04-02 | — | — | EP | disclosed |
| US-6350759-B1 | ANTIOXIDATIVE AGENTS FOR OXIDATION STRESS, ESPECIALLY AT THE CEREBRAL LEVEL; | ADIR ET COMPAGNIE (FR) | 2002-02-26 | — | — | US | disclosed |
| US-6093744-A | USE AS CEREBROVASCULAR AGENTS IN DISEASES SUCH AS STROKE, PERIPHERAL VASCULAR DISEASE, RESTENOSIS, AND AS AGENTS FOR REGULATING PLASMA CHOLESTEROL CONCENTRATIONS, FOR TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0995743-A1 | Derivatives of dihydro- and tetrahydrochinoline as a medicinal antioxydans | ADIR ET COMPAGNIE (FR) | 2000-04-26 | — | — | EP | disclosed |
| US-3933927-A | Phenol transalkylation process | ETHYL CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | MEN1 4335/4885KMT2A 1474/4885HTT 4697/4885 |
| US-20120029235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | MEN1 4869/4885KMT2A 1737/4885HTT 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.